ANI Pharmaceuticals Inc (ANIP)vsHaleon plc (HLN)
ANIP
ANI Pharmaceuticals Inc
$70.19
-1.78%
HEALTHCARE · Cap: $1.64B
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1040% more annual revenue ($11.15B vs $978.38M). HLN leads profitability with a 14.5% profit margin vs 11.1%. ANIP appears more attractively valued with a PEG of 1.06. ANIP earns a higher WallStSmart Score of 76/100 (B+).
ANIP
Strong Buy76
out of 100
Grade: B+
HLN
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 191.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 25.9% year-over-year
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIP
The strongest argument for ANIP centers on EPS Growth, P/E Ratio, Price/Book. Revenue growth of 25.9% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : ANIP
The primary concerns for ANIP are Altman Z-Score, Market Cap.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
ANIP profiles as a growth stock while HLN is a value play — different risk/reward profiles.
ANIP carries more volatility with a beta of 0.45 — expect wider price swings.
ANIP is growing revenue faster at 25.9% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
ANIP scores higher overall (76/100 vs 51/100) and 25.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?